GT Biopharma, Inc. (GTBP) Balance Sheet
As of 2026-06-30 (10-Q), GT Biopharma, Inc. (GTBP) reported total assets of $5.8M and shareholders' equity of $3.6M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $5.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GTBPGT Biopharma, Inc.Follow GTBP — free
—
Price chart with a free account
- Market cap
- 9.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 12 Nov, in 19 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 0.1 | 0.1 | 0.0 | 0.9 | 0.0 | 0.0 | 0.6 | 0.1 | 0.0 | 5.3 | 9.0 | 5.7 | 1.1 | 4.0 | 6.9 | 5.1 | |
| Short-term investments | — | — | — | — | — | — | — | — | — | 0.0 | 23.0 | 10.8 | 12.9 | — | — | — | |
| Receivables | — | 0.0 | 0.0 | 0.0 | — | — | — | — | — | — | — | — | — | — | — | — | |
| Inventory | 0.0 | 0.1 | 0.0 | 0.0 | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current assets | 0.1 | 0.2 | 0.1 | 0.9 | 0.0 | 0.0 | 0.6 | 0.1 | 0.3 | 5.7 | 32.2 | 16.6 | 14.1 | 4.2 | 8.1 | 5.8 | |
| Total assets | 0.1 | 0.2 | 0.1 | 0.9 | 0.1 | 0.0 | 254.4 | 25.4 | 0.4 | 5.7 | 32.2 | 16.7 | 14.1 | 4.2 | 8.1 | 5.8 | |
| Current liabilities | 5.2 | 6.6 | 6.4 | 29.8 | 49.9 | 18.9 | 2.7 | 14.0 | 19.7 | 35.1 | 10.3 | 4.9 | 6.6 | 5.9 | 2.3 | 2.2 | |
| Long-term debt | — | — | — | — | — | — | — | — | 2.5 | 2.5 | — | — | — | — | — | — | |
| Short-term debt | — | — | — | — | — | — | — | — | 13.3 | 30.8 | — | — | — | — | — | — | |
| Total liabilities | 5.2 | 6.6 | 6.5 | 30.5 | 50.6 | 18.9 | 2.7 | 14.0 | 19.7 | — | 10.3 | 5.0 | 6.6 | — | — | — | |
| Shareholders' equity | -5.1 | -6.3 | -6.3 | -29.6 | -50.6 | -18.9 | 251.7 | 11.4 | -19.3 | -29.4 | 21.9 | 11.7 | 7.5 | -1.7 | 5.8 | 3.6 |
USD millions · SEC XBRL
GT Biopharma, Inc. — questions
- How much cash does GT Biopharma, Inc. have?
- $5.1M in cash and cash equivalents as of 2026-06-30.
- What are GT Biopharma, Inc.'s total assets?
- $5.8M as of 2026-06-30.
- What is GT Biopharma, Inc.'s shareholders' equity?
- $3.6M as of 2026-06-30.
Every figure on this page comes from GT Biopharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.